BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10462249)

  • 1. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy.
    Caley IJ; Betts MR; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    Vaccine; 1999 Aug; 17(23-24):3124-35. PubMed ID: 10462249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
    Caley IJ; Betts MR; Irlbeck DM; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    J Virol; 1997 Apr; 71(4):3031-8. PubMed ID: 9060663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.
    Ljungberg K; Whitmore AC; Fluet ME; Moran TP; Shabman RS; Collier ML; Kraus AA; Thompson JM; Montefiori DC; Beard C; Johnston RE
    J Virol; 2007 Dec; 81(24):13412-23. PubMed ID: 17913817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.
    Fluet ME; Whitmore AC; Moshkoff DA; Fu K; Tang Y; Collier ML; West A; Moore DT; Swanstrom R; Johnston RE; Davis NL
    Virology; 2008 Jan; 370(1):22-32. PubMed ID: 17904185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
    Perri S; Greer CE; Thudium K; Doe B; Legg H; Liu H; Romero RE; Tang Z; Bin Q; Dubensky TW; Vajdy M; Otten GR; Polo JM
    J Virol; 2003 Oct; 77(19):10394-403. PubMed ID: 12970424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
    Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
    J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.
    Harrington PR; Yount B; Johnston RE; Davis N; Moe C; Baric RS
    J Virol; 2002 Jan; 76(2):730-42. PubMed ID: 11752163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.
    Davis NL; Brown KW; Johnston RE
    J Virol; 1996 Jun; 70(6):3781-7. PubMed ID: 8648713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
    J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus.
    Bennett AM; Lescott T; Phillpotts RJ
    Viral Immunol; 1998; 11(3):109-17. PubMed ID: 9918402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.
    Fouts TR; Tuskan RG; Chada S; Hone DM; Lewis GK
    Vaccine; 1995 Dec; 13(17):1697-705. PubMed ID: 8719522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.
    Balasuriya UB; Heidner HW; Hedges JF; Williams JC; Davis NL; Johnston RE; MacLachlan NJ
    J Virol; 2000 Nov; 74(22):10623-30. PubMed ID: 11044106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant.
    Davis NL; Willis LV; Smith JF; Johnston RE
    Virology; 1989 Jul; 171(1):189-204. PubMed ID: 2525837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.
    Gupta S; Janani R; Bin Q; Luciw P; Greer C; Perri S; Legg H; Donnelly J; Barnett S; O'Hagan D; Polo JM; Vajdy M
    J Virol; 2005 Jun; 79(11):7135-45. PubMed ID: 15890953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
    J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.